Conmed’s Downside Magnet: Why the Stock Swallows More Losses Than Gains

Four risk flags and a deep drawdown history signal heightened vulnerability in a bullish, high‑volatility market

CNMD CONMED Corporation

In this report

01

Returns Overview

Period returns, alpha, cumulative performance, distributions

P. 2-3

→

02

Volatility Analysis

Annualized volatility, downside deviation, drawdowns

P. 4-5

→

03

Beta & Correlation

Trailing, upside, downside beta, systematic risk

P. 6-7

→

04

Risk-Adjusted Returns

Sharpe, Sortino, Calmar, Information, Treynor

P. 8-9

→

05

Market Regime Analysis

Bull/bear behavior, capture ratios

P. 10-11

→

06

Investment Highlights & Risk Summary

Executive summary, risk flags, rankings

P. 12-13

→

Returns Overview

CONMED Corporation (CNMD) — Return Performance

Conmed Corporation (CNMD) has underperformed its healthcare sector benchmark across all horizons, delivering negative total returns while the sector posted positive gains over the same periods. Over the past month the stock fell 1.51% versus a sector alpha of +1.08%, and this outperformance gap widens to -145.19% alpha over five years, indicating persistent lagging performance relative to XLV.

Period Returns vs S&P 500 & XLV

Monthly Returns Heatmap

CNMD

The stock generated negative alpha in every interval, with the most pronounced divergence occurring at longer horizons—alpha of -139.38% over three years and -145.19% over five years—signaling structural underperformance. Short-term periods show modest shortfalls (e.g., -3.88% sector alpha in one month), but the cumulative effect compounds, making CNMD a consistent laggard relative to its healthcare peers.

Returns Overview

CONMED Corporation (CNMD) — Return Charts

Volatility Analysis

CONMED Corporation (CNMD) — Volatility Profile

CONMED Corporation (CNMD) exhibits markedly higher price variability than the broader market, with an annualized volatility of 38.09% compared to the S&P 500's 17.78%, indicating more than double the typical daily price swings. The stock’s downside risk is pronounced: a downside deviation of 29.71% signals that negative returns are substantially larger than the overall volatility figure, while a maximum drawdown of -78.13% over a five‑year horizon underscores severe capital erosion without any sign of recovery to date. Recent short‑term volatility remains elevated, as the 60‑day and 252‑day volatilities (41.87% and 39.09%) both sit above the long‑term average of 38.09%, suggesting that price swings have intensified rather than subsided.

Volatility Metrics

CNMD

The company’s volatility profile is considerably more aggressive than the S&P 500 benchmark, reflecting heightened sensitivity to market and firm‑specific news. Downside metrics reveal a steep risk tilt: the downside deviation of 29.71% exceeds half of the total annualized volatility, and the -78.13% max drawdown—spanning from November 2021 to June 2026 with no recovery—highlights an extended period of sustained loss that would be material for most investors. Moreover, both the 60‑day (41.87%) and 252‑day (39.09%) volatilities are above the long‑term average, indicating that recent price movements have been more erratic than historically typical.

CNMD’s annualized volatility is over double the S&P 500’s level.
Downside deviation of 29.71% signals a strong asymmetry toward negative returns.
Maximum drawdown of -78.13% represents severe capital loss with no recovery to date.
Both short‑term (60d) and medium‑term (252d) volatilities exceed the long‑run average, implying heightened recent risk.

Positive Characteristics
The elevated volatility may provide larger upside potential for risk‑tolerant investors seeking price dislocation opportunities.

Volatility Analysis

CONMED Corporation (CNMD) — Volatility & Drawdown Charts

Beta & Correlation

CONMED Corporation (CNMD) — Beta Profile

CONMED Corporation exhibits a trailing beta of 1.125 versus the S&P 500, placing it in the market‑like range (0.8–1.2). This indicates that, on average, the stock moves slightly more than the broader market during normal conditions, offering modest upside potential but also heightened exposure to market swings. The asymmetric betas—upside beta of 1.111 and downside beta of 1.223—reveal a steeper decline in down markets, suggesting that risk managers should weight downside scenarios more heavily when stress‑testing portfolios.

Beta & Correlation Metrics

CNMD

The market beta of 1.125 signals that CONMED’s price tends to amplify overall equity movements by about 12.5% on the upside and downside, though the higher downside beta (1.223) points to a sharper fall when markets retreat. With an R‑squared of 27.6%, only roughly one‑quarter of the stock’s variance is explained by market factors; the remaining 72.4% is idiosyncratic, implying that diversification benefits are substantial. Compared with its healthcare sector benchmark XLV, CONMED’s sector beta of 1.098 and sector correlation of 0.483 indicate that sector dynamics account for less than half of its price movements, reinforcing the view that company‑specific drivers dominate risk exposure.

Trailing market beta (1.125) classifies CONMED as market‑like rather than defensive or aggressively volatile.
Downside beta (1.223) exceeds upside beta (1.111), highlighting asymmetric downside risk.
R‑squared of 27.6% shows limited explanatory power from the broader market, emphasizing diversification potential.
Systematic risk comprises only 27.6% of total variance; idiosyncratic risk dominates at 72.4%.
Sector beta (1.098) is slightly lower than market beta, indicating that sector exposure contributes less to overall volatility than company‑specific factors.

Positive Characteristics
The modest market‑like beta suggests CONMED can capture general equity upside without the extreme swings of high‑beta stocks.
A low R‑squared and high idiosyncratic risk component provide meaningful diversification benefits within a broader portfolio.
Sector correlation (0.483) below the market correlation (0.525) implies that sector movements are less predictive, allowing investors to hedge sector risk independently.

Beta & Correlation

CONMED Corporation (CNMD) — Rolling Beta

Positive Notes

The modest market‑like beta suggests CONMED can capture general equity upside without the extreme swings of high‑beta stocks.

A low R‑squared and high idiosyncratic risk component provide meaningful diversification benefits within a broader portfolio.

Sector correlation (0.483) below the market correlation (0.525) implies that sector movements are less predictive, allowing investors to hedge sector risk independently.

Risk-Adjusted Returns

CONMED Corporation (CNMD) — Risk-Adjusted Performance

The risk‑adjusted profile of CONMED Corporation (CNMD) reflects modest compensation for the volatility it has assumed over the analysis period. With a Sharpe ratio of 0.068, the stock delivers far less excess return per unit of total risk than the benchmark threshold of 1.0, indicating that its performance barely exceeds the risk‑free rate after accounting for overall volatility. However, the Sortino ratio of 0.088 is slightly higher than the Sharpe, suggesting that downside volatility has been marginally lower than total volatility and that the equity’s return distribution is modestly skewed toward fewer severe losses.

Risk-free rate: 3.63% (Fed Funds Rate)

Risk-Adjusted Metrics

CNMD

CONMED's Calmar ratio of 0.08 signals a weak return‑to‑drawdown relationship; the firm’s worst peak‑to‑trough loss has been roughly twelve times larger than its annualized excess return, highlighting susceptibility to deep drawdowns. The negative Information Ratio of -0.202 further implies that active management has underperformed its benchmark on a risk‑adjusted basis, generating less alpha than expected given the level of systematic exposure. Nonetheless, the Treynor ratio of 2.314 indicates that for each unit of market beta, the stock has produced a relatively high excess return, reflecting a favorable reward for bearing systematic risk despite poor total‑risk metrics.

Sharpe (0.068) and Sortino (0.088) are both well below the “good” threshold, showing limited excess return relative to volatility.
The slight edge of Sortino over Sharpe points to a marginally better downside‑risk profile than total risk.
A Calmar ratio of 0.08 reveals that drawdowns have severely eroded returns, indicating high tail‑risk exposure.
Negative Information Ratio (-0.202) suggests the stock has not delivered consistent alpha relative to its benchmark.
Treynor ratio (2.314) is comparatively strong, implying that systematic risk has been compensated more generously than total risk.

Positive Characteristics
The Sortino ratio exceeds the Sharpe, indicating a relatively less volatile downside performance.
A Treynor ratio above 2.0 reflects solid compensation for market‑related (beta) risk.

Risk-Adjusted Returns

CONMED Corporation (CNMD) — Rolling Sharpe & Sortino

Positive Notes

The Sortino ratio exceeds the Sharpe, indicating a relatively less volatile downside performance.

A Treynor ratio above 2.0 reflects solid compensation for market‑related (beta) risk.

Market Regime Analysis

CONMED Corporation (CNMD) — Regime Behavior

The analysis of CONMED Corporation (CNMD) across distinct market regimes reveals a pronounced sensitivity to volatility within bullish environments and heightened vulnerability during bearish periods. In the Bull‑HighVol regime, CNMD delivers an average monthly return of 2.14%, substantially outpacing its performance in the calmer Bull‑LowVol setting where returns compress to 0.43%. Conversely, the stock struggles in bear markets, posting a -2.66% loss on average during Bear‑LowVol months and a less severe yet still negative -1.67% during Bear‑HighVol intervals. The upside capture of 82.8% combined with a downside capture of 124.0% yields a capture ratio of 0.67, indicating that the stock lags the broader market on the upside while amplifying losses on the downside.

Current Market Regime: Bull-HighVol

Bull-LowVol = calm uptrend • Bull-HighVol = volatile uptrend • Bear-LowVol = orderly decline • Bear-HighVol = crisis

Regime Returns & Capture Ratios

CNMD

During Bull‑HighVol periods, CNMD’s elevated average return suggests it benefits from heightened market enthusiasm, likely driven by its exposure to growth-oriented medical device spending that accelerates when investors favor riskier assets. In contrast, the modest 0.43% gain in Bull‑LowVol conditions points to limited upside participation when market momentum is subdued and volatility low. The negative performance in both bear regimes—especially the -2.66% average loss in Bear‑LowVol—highlights a defensive weakness; CNMD does not act as a shelter during orderly declines, reflecting its reliance on discretionary capital expenditures that tend to be cut first in tightening cycles. The current Bull‑HighVol regime amplifies these dynamics, positioning CNMD for potentially strong short‑term upside but also exposing it to rapid reversals should volatility subside or market sentiment shift.

Market Regime Analysis

CONMED Corporation (CNMD) — Regime & Capture Charts

Regime Timeline

CNMD’s average return spikes to 2.14% in Bull‑HighVol, more than five times its performance in Bull‑LowVol.
Downside capture exceeds 100% (124.0%), meaning the stock loses more than the market during bear periods.
The capture ratio of 0.67 signals a net asymmetry favoring downside risk over upside potential.
In Bear‑LowVol months, CNMD suffers the steepest average decline (-2.66%), indicating limited defensive characteristics.
Current Bull‑HighVol conditions align with CNMD’s strongest historical regime performance.

Positive Characteristics
Strong upside in volatile bullish markets suggests opportunistic buying during periods of heightened market activity.
The stock’s high upside capture relative to its modest beta indicates that when the market rallies sharply, CNMD can participate meaningfully.

Investment Highlights & Risk Summary

CONMED Corporation (CNMD) — Summary & Implications

The analysis of CONMED Corporation (CNMD) reveals a challenging performance backdrop over the past year, marked by a 1‑year total return of -32.23% and an alpha of -51.23% versus the S&P 500, indicating substantial underperformance relative to both broad market and its healthcare sector peers (sector alpha -46.76%). Risk metrics underscore heightened exposure: annualized volatility stands at 38.09%, beta is modestly above market at 1.125, yet the Sharpe ratio of 0.068 and Sortino ratio of 0.088 signal minimal excess return per unit of risk. The downside capture of 124% versus an upside capture of 82.8% highlights a pronounced asymmetry, meaning the stock tends to lose more on market declines than it gains on rallies. While these figures suggest significant downside risk, the company’s beta and volatility are comparable to other small‑cap healthcare firms, offering potential diversification benefits for portfolios seeking exposure to niche medical device segments, provided investors are comfortable with the drawdown profile.

Summary Dashboard

Investment Highlights

Beta of 1.125 indicates that CNMD moves roughly in line with market direction, allowing it to participate in broader equity rallies.
Upside capture of 82.8% shows the stock retains a sizable share of market gains during positive periods, offering upside participation despite overall underperformance.
The company operates within the healthcare sector, which historically provides defensive characteristics and long‑term demand stability for medical devices.

Risk-Return Rankings

CNMD HIGH

Elevated volatility and deep drawdown dominate a modest beta profile, resulting in a high risk‑adjusted cost.

Strength: Upside capture of 82.8% provides participation in market rallies.

Concern: Maximum drawdown of -78.13% reflects severe capital loss potential.

Key Takeaways

CNMD has underperformed both the S&P 500 and its healthcare sector by over 45% on a risk‑adjusted basis in the past year.
The stock’s volatility (38.09%) and maximum drawdown (-78.13%) are substantially higher than typical large‑cap equities, indicating heightened downside risk.
Sharpe (0.068) and Sortino (0.088) ratios are far below the benchmark of 1.0, suggesting poor compensation for the risk taken.
Downside capture exceeding 100% (124%) means the stock loses more than the market during declines, an asymmetry that investors must monitor.

PORTFOLIO IMPLICATIONS

Given its high volatility and deep drawdown history, CNMD is best suited for a small allocation within a diversified portfolio that already contains lower‑beta, higher‑Sharpe assets. Its modest upside capture can add incremental return potential during market uptrends, but the pronounced downside asymmetry warrants tight risk controls, such as stop‑loss orders or position sizing limits. Investors seeking exposure to niche medical device markets should weigh CNMD against more stable healthcare peers to ensure that its risk profile aligns with their overall portfolio tolerance.

CNMD

Related Reports

Visit finexus.net/reports for more reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.